Adaptimmune Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $40,901 | $128,231 | $5,678 | $233 |
Gross Profit | 40,901 | 125,629 | 2,849 | -2,641 |
EBITDA | -12,859 | 71,014 | -46,431 | -49,848 |
EBIT | -15,677 | 68,269 | -49,259 | -52,723 |
Net Income | -17,617 | 69,521 | -48,503 | -48,333 |
Net Change In Cash | 40,901 | 128,231 | 5,678 | 233 |
Free Cash Flow | -54,886 | 46,631 | -32,289 | -15,492 |
Cash | 116,741 | 211,810 | 140,670 | 143,991 |
Basic Shares | 255,768 | 259,863 | 241,873 | 227,112 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $60,281 | $27,148 | $6,149 | $3,958 |
Gross Profit | 50,423 | -100,578 | -104,941 | -87,610 |
EBITDA | -128,198 | -155,593 | -155,679 | -125,811 |
EBIT | -138,038 | -161,664 | -162,245 | -133,464 |
Net Income | -113,871 | -165,456 | -158,090 | -130,092 |
Net Change In Cash | 60,281 | 27,148 | 6,149 | 3,958 |
Cost of Revenue | 89,817 | 7,536 | ||
Free Cash Flow | -145,760 | -171,509 | 1,948 | -56,497 |
Cash | 143,991 | 108,033 | 149,948 | 56,882 |
Basic Shares | 201,073 | 161,207 | 155,805 | 142,463 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.01 |
2024-06-30 | $0.24 |
2024-03-31 | -$0.18 |
2023-12-31 | -$0.24 |
